Adage Capital Partners Gp, L.L.C. Kura Oncology, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.01 - $19.45 $300,250 - $486,250	-25,000 Reduced 5.56%	425,000 $5.81 Million
Q2 2022 Aug 15, 2022	BUY	$10.71 - $18.33 $2.14 Million - $3.67 Million	200,000 Added 80.0%	450,000 $8.25 Million
Q1 2022 May 16, 2022	BUY	$11.78 - $16.98 $2.95 Million - $4.25 Million	250,000 New	250,000 $4.02 Million
Q4 2020 Feb 16, 2021	SELL	$29.0 - $41.62 $43.5 Million - $62.4 Million	-1,500,450 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $5.04 Million - $9.47 Million	-309,000 Reduced 17.08%	1,500,450 $46 Million
Q2 2020 Aug 14, 2020	BUY	$7.95 - $18.81 $10 Million - $23.7 Million	1,259,450 Added 228.99%	1,809,450 $29.5 Million
Q1 2020 May 15, 2020	BUY	$6.45 - $14.04 $3.23 Million - $7.02 Million	500,000 Added 1000.0%	550,000 $5.47 Million
Q1 2019 May 15, 2019	BUY	$13.73 - $16.87 $686,500 - $843,500	50,000 New	50,000 $830,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.